应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
00512 远大医药
已收盘 07-17 16:08:34
4.580
+0.000
0.00%
最高
4.630
最低
4.530
成交量
109.82万
今开
4.630
昨收
4.580
日振幅
2.18%
总市值
162.57亿
流通市值
162.57亿
总股本
35.50亿
成交额
503.07万
换手率
0.03%
流通股本
35.50亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
远大医药完成对天津田边和百济制药的收购
新京报 · 21:36
远大医药完成对天津田边和百济制药的收购
优势领域同步发力,远大医药(00512)完成收购天津田边及百济制药,加码慢性疾病及过敏性鼻炎两大赛道
智通财经网 · 17:58
优势领域同步发力,远大医药(00512)完成收购天津田边及百济制药,加码慢性疾病及过敏性鼻炎两大赛道
远大医药(00512)完成对天津田边和百济制药的收购
智通财经 · 17:47
远大医药(00512)完成对天津田边和百济制药的收购
远大医药(00512.HK)完成收购两间医药相关公司
阿斯达克财经 · 17:34
远大医药(00512.HK)完成收购两间医药相关公司
南向资金7月10日净买入远大医药57.30万股 连续5日增持
自选股智能写手 · 07-11
南向资金7月10日净买入远大医药57.30万股 连续5日增持
远大医药:2023年年报的补充公告,其中再次提到了公司的股份奖励计划 截至2023年十二月三十一日,该计划的有效年期还剩下约七年半
金融界港股 · 07-05
远大医药:2023年年报的补充公告,其中再次提到了公司的股份奖励计划 截至2023年十二月三十一日,该计划的有效年期还剩下约七年半
远大医药07月02日主力资金流出68万元 连续3日减仓
自选股智能写手 · 07-02
远大医药07月02日主力资金流出68万元 连续3日减仓
董事会主席兼执行董事唐纬坤增持远大医药(00512)5万股 每股作价4.68港元
智通财经网 · 06-28
董事会主席兼执行董事唐纬坤增持远大医药(00512)5万股 每股作价4.68港元
天津发展(00882)附属拟以1.2亿元向远大医药(中国)出售其于天津田边持有的24.65%股权
智通财经 · 06-28
天津发展(00882)附属拟以1.2亿元向远大医药(中国)出售其于天津田边持有的24.65%股权
力生制药:与远大医药就田边制药24.65%股权转让签订合同
财通社 · 06-28
力生制药:与远大医药就田边制药24.65%股权转让签订合同
远大医药(00512):邢丽娜获委任为非执行董事
智通财经 · 06-24
远大医药(00512):邢丽娜获委任为非执行董事
远大医药(00512.HK):邢丽娜被委任为非执行董事
格隆汇资讯 · 06-24
远大医药(00512.HK):邢丽娜被委任为非执行董事
南向资金6月14日净卖出远大医药54.95万股 连续3日减持
自选股智能写手 · 06-17
南向资金6月14日净卖出远大医药54.95万股 连续3日减持
远大医药06月14日主力资金流出230万元 连续3日减仓
自选股智能写手 · 06-14
远大医药06月14日主力资金流出230万元 连续3日减仓
远大医药06月13日遭主力抛售288万元 环比增加294.52%
自选股智能写手 · 06-13
远大医药06月13日遭主力抛售288万元 环比增加294.52%
远大医药(00512.HK)创新眼科药物完成首例患者入组给药
阿斯达克财经 · 06-12
远大医药(00512.HK)创新眼科药物完成首例患者入组给药
远大医药GPN00884国内I期临床完成首例患者入组给药
证券时报网 · 06-11
远大医药GPN00884国内I期临床完成首例患者入组给药
远大医药(00512):全球创新眼科药物GPN00884在中国开展的I期临床研究完成了首例患者入组给药
智通财经 · 06-11
远大医药(00512):全球创新眼科药物GPN00884在中国开展的I期临床研究完成了首例患者入组给药
远大医药(00512)GPN00884国内I期临床完成首例患者入组给药,或破局过亿近视防治市场
智通财经 · 06-11
远大医药(00512)GPN00884国内I期临床完成首例患者入组给药,或破局过亿近视防治市场
远大医药06月07日获主力加仓259万元 环比增加4216.67%
自选股智能写手 · 06-07
远大医药06月07日获主力加仓259万元 环比增加4216.67%
加载更多
公司概况
公司名称:
远大医药
所属市场:
SEHK
上市日期:
--
主营业务:
远大医药健康控股有限公司是一家主要从事制造及销售医药制剂及医疗器械的香港投资控股公司。该公司主要从事制造及销售医药制剂及医疗器械、生物技术产品及营养产品、精品原料药和其他产品。该公司的主要产品涵盖抗肿瘤、心血管急救制剂及高端心脑血管介入医疗器械、抗病毒抗感染、呼吸及五官科以及生物健康产品和精品原料药。
发行价格:
--
{"stockData":{"symbol":"00512","market":"HK","secType":"STK","nameCN":"远大医药","latestPrice":4.58,"timestamp":1721203714010,"preClose":4.58,"halted":0,"volume":1098165,"delay":0,"floatShares":3549571148,"shares":3549571148,"eps":0.535954,"marketStatus":"已收盘","marketStatusCode":5,"change":0,"latestTime":"07-17 16:08:34","open":4.63,"high":4.63,"low":4.53,"amount":5030693,"amplitude":0.021834,"askPrice":4.58,"askSize":3000,"bidPrice":4.56,"bidSize":11000,"shortable":3,"etf":0,"ttmEps":0.535954,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1721266200000},"adr":0,"listingDate":819302400000,"adjPreClose":4.58,"dividendRate":0.056769,"openAndCloseTimeList":[[1721179800000,1721188800000],[1721192400000,1721203200000]],"volumeRatio":0.525916,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/00512","defaultTab":"news","newsList":[{"id":"2452415750","title":"远大医药完成对天津田边和百济制药的收购","url":"https://stock-news.laohu8.com/highlight/detail?id=2452415750","media":"新京报","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452415750?lang=zh_cn&edition=full","pubTime":"2024-07-17 21:36","pubTimestamp":1721223379,"startTime":"0","endTime":"0","summary":"新京报讯(记者王卡拉)7月17日,远大医药发布公告,公司近日分别完成对天津田边制药(简称“天津田边”)、南昌百济制药有限公司和江西百安百亿医药科技有限公司(两者合称“百济制药”)100%股权的变更登记,两项收购将会进一步深化其在心脑血管急救板块和呼吸及危重症板块的产业布局。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202407173133554195.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202407173133554195.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","00512","01477","BK1191"],"gpt_icon":0},{"id":"2452362171","title":"优势领域同步发力,远大医药(00512)完成收购天津田边及百济制药,加码慢性疾病及过敏性鼻炎两大赛道","url":"https://stock-news.laohu8.com/highlight/detail?id=2452362171","media":"智通财经网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452362171?lang=zh_cn&edition=full","pubTime":"2024-07-17 17:58","pubTimestamp":1721210294,"startTime":"0","endTime":"0","summary":"公司对天津田边制药有限公司,以及南昌百济制药有限公司和江西百安百煜医药科技有限公司(两者合称:百济制药)100%股权的变更登记已顺利完成...","market":"sg","thumbnail":"https://img.zhitongcaijing.com/image/20240717/20240717175857_58564.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20240717/20240717175857_58564.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1152127.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["01477","BK1574","BK1191","00512"],"gpt_icon":0},{"id":"2452136399","title":"远大医药(00512)完成对天津田边和百济制药的收购","url":"https://stock-news.laohu8.com/highlight/detail?id=2452136399","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452136399?lang=zh_cn&edition=full","pubTime":"2024-07-17 17:47","pubTimestamp":1721209651,"startTime":"0","endTime":"0","summary":"智通财经APP讯,远大医药 发布公告,集团近日分别完成了对天津田边制药有限公司以及南昌百济制药有限公司和江西百安百煜医药科技有限公司100%股权的变更登记,这两项收购将会进一步深化集团在心脑血管急救板块和呼吸及危重症板块的产业布局。兹提述公司日期为2023年12月21日内容有关集团拟收购天津田边控股股权。集团附属公司北京远大九和药业有限公司近日以约2.6亿元人民币收购了百济制药100%的股权并获得其技术领先的鼻喷制剂平台。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1152102.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","01477","00512","BK1574"],"gpt_icon":0},{"id":"2452613546","title":"远大医药(00512.HK)完成收购两间医药相关公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2452613546","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452613546?lang=zh_cn&edition=full","pubTime":"2024-07-17 17:34","pubTimestamp":1721208840,"startTime":"0","endTime":"0","summary":"远大医药公布,于近日分别完成对天津田边制药有限公司,以及南昌百济制药有限公司和江西百安百煜医药科技有限公司100%股权的变更登记。公司表示,上述两项收购将会进一步深化集团在心脑血管急救板块和呼吸及危重症板块的产业布局。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20240508115940532_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20240508115940532_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1364370/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["159938","BK1161","BK1574","BK1191","BK1515","09939","00512"],"gpt_icon":0},{"id":"2450587141","title":"南向资金7月10日净买入远大医药57.30万股 连续5日增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2450587141","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450587141?lang=zh_cn&edition=full","pubTime":"2024-07-11 09:31","pubTimestamp":1720661490,"startTime":"0","endTime":"0","summary":"7月10日, 南向资金增持远大医药57.30万股,连续5日增持。截止当日收盘,港股通共持有远大医药33391.31万股,占流通股9.40%。港股通增持金额前五个股分别为中国移动、建设银行、中远海控、农夫山泉、工商银行。远大医药近5个交易日下跌1.88%,港股通累计增持220.40万股;近20个交易日下跌2.70%,港股通累计增持641.05万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407110942279f3114f4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407110942279f3114f4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","00512"],"gpt_icon":0},{"id":"2449571240","title":"远大医药:2023年年报的补充公告,其中再次提到了公司的股份奖励计划 截至2023年十二月三十一日,该计划的有效年期还剩下约七年半","url":"https://stock-news.laohu8.com/highlight/detail?id=2449571240","media":"金融界港股","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449571240?lang=zh_cn&edition=full","pubTime":"2024-07-05 18:15","pubTimestamp":1720174546,"startTime":"0","endTime":"0","summary":"金融界7月5日消息,远大医药近日发布了2023年年报的补充公告,其中再次提到了公司的股份奖励计划。该计划旨在认可被选定参与者的贡献,并激励他们留在集团中,从而促进集团的持续经营、成长和发展。根据计划规则的详细介绍,该计划将有效十年,即自生效日期起计十年期间。截至2023年十二月三十一日,该计划的有效年期还剩下约七年半。以上补充资料并不影响年报中的其他内容。\n\n\r\n 责任编辑:山上","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/07/05181541399275.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["00512","BK1191"],"gpt_icon":0},{"id":"2448821841","title":"远大医药07月02日主力资金流出68万元 连续3日减仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2448821841","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448821841?lang=zh_cn&edition=full","pubTime":"2024-07-02 16:16","pubTimestamp":1719908218,"startTime":"0","endTime":"0","summary":"07月02日, 远大医药股价涨0.43%,报收4.67元,成交金额1154万元,换手率0.07%,振幅2.15%,量比1.06。远大医药今日主力资金净流出68万元,连续3日净流出,上一交易日主力净流出45万元,今日环比增加51.11%。近一年数据显示,该股主力连续3日净流出后,次日下跌概率为60.00%,平均跌幅为1.64%。该股近5个交易日下跌1.27%,主力资金累计净流出366万元,其中1个交易日为股价上涨时净流出;近20日主力资金累计净流出549万元,其中净流出天数为10日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407021617199ef319af&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407021617199ef319af&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","00512"],"gpt_icon":0},{"id":"2446502868","title":"董事会主席兼执行董事唐纬坤增持远大医药(00512)5万股 每股作价4.68港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2446502868","media":"智通财经网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446502868?lang=zh_cn&edition=full","pubTime":"2024-06-28 20:25","pubTimestamp":1719577558,"startTime":"0","endTime":"0","summary":"6月28日,董事会主席兼执行董事唐纬坤增持远大医药(00512)5万股,每股作价4.68港元,总金额为23.4万港元。","market":"us","thumbnail":"https://img.zhitongcaijing.com/image/20240628/20240628202625_14869.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20240628/20240628202625_14869.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1142865.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1191","00512"],"gpt_icon":0},{"id":"2446571882","title":"天津发展(00882)附属拟以1.2亿元向远大医药(中国)出售其于天津田边持有的24.65%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2446571882","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446571882?lang=zh_cn&edition=full","pubTime":"2024-06-28 17:50","pubTimestamp":1719568234,"startTime":"0","endTime":"0","summary":"智通财经APP讯,天津发展(00882)发布公告,有关力生制药(公司间接非全资附属公司)透过于天津产权交易中心公开挂牌出售程序潜在出售其于天津田边持有的24.65%股权。于2024年6月28日,力生制药与最终中标者远大医药(中国)就出售事项订立产权交易合同,总代价为人民币1.20亿元。于出售事项完成后,集团将不再持有天津田边任何权益。公告称,出售事项符合力生制药的整体战略规划。董事会认为,出售事项将提升集团资产的营运效率、优化集团的资源分配及加强集团的现金流。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1142540.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["00512","BK1191","BK1232","00882"],"gpt_icon":0},{"id":"2446224095","title":"力生制药:与远大医药就田边制药24.65%股权转让签订合同","url":"https://stock-news.laohu8.com/highlight/detail?id=2446224095","media":"财通社","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446224095?lang=zh_cn&edition=full","pubTime":"2024-06-28 15:51","pubTimestamp":1719561060,"startTime":"0","endTime":"0","summary":"力生制药公告,公司基于整体规划和市场竞争情况,决定以不低于12029.20万元的底价公开挂牌转让所持田边制药24.65%股权。挂牌期间,远大医药成为唯一意向受让方,并最终以12029.20万元成交。双方已签订产权交易合同,转让价款将一次性支付。此次股权转让符合公司战略部署,对公司经营业绩和财务状况的具体影响将以年终审计结果为准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024062815521895e1bc7c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024062815521895e1bc7c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01477","00512","BK1191","BK1574"],"gpt_icon":0},{"id":"2445596028","title":"远大医药(00512):邢丽娜获委任为非执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2445596028","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2445596028?lang=zh_cn&edition=full","pubTime":"2024-06-24 17:01","pubTimestamp":1719219674,"startTime":"0","endTime":"0","summary":"智通财经APP讯,远大医药(00512)发布公告,史琳博士(史博士)因有意投放更多时间处理个人事务,已提出辞任公司的执行董事,于2024年6月24日起生效。邢丽娜博士(邢博士)已被委任为公司的非执行董事,于2024年6月24日起生效。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1139437.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["00512","BK1191"],"gpt_icon":0},{"id":"2445238590","title":"远大医药(00512.HK):邢丽娜被委任为非执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2445238590","media":"格隆汇资讯","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2445238590?lang=zh_cn&edition=full","pubTime":"2024-06-24 17:01","pubTimestamp":1719219665,"startTime":"0","endTime":"0","summary":"格隆汇6月24日丨远大医药(00512.HK)发布公告,史琳因有意投放更多时间处理个人事务,已提出辞任公司的执行董事,于2024年6月24日起生效。邢丽娜已被委任为公司的非执行董事,于2024年6月24日起生效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406241701159f5f287f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406241701159f5f287f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","00512"],"gpt_icon":0},{"id":"2444185553","title":"南向资金6月14日净卖出远大医药54.95万股 连续3日减持","url":"https://stock-news.laohu8.com/highlight/detail?id=2444185553","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2444185553?lang=zh_cn&edition=full","pubTime":"2024-06-17 09:31","pubTimestamp":1718587893,"startTime":"0","endTime":"0","summary":"6月14日,南向资金减持远大医药54.95万股连续3日减持。截止当日收盘,港股通共持有远大医药32576.66万股,占流通股9.17%。港股通减持金额前五个股分别为中国铁塔、中远海能、招商银行、香港交易所、中国宏桥。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406170945599f446f4b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406170945599f446f4b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["00512","BK1191"],"gpt_icon":0},{"id":"2443857648","title":"远大医药06月14日主力资金流出230万元 连续3日减仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2443857648","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2443857648?lang=zh_cn&edition=full","pubTime":"2024-06-14 16:15","pubTimestamp":1718352952,"startTime":"0","endTime":"0","summary":"06月14日, 远大医药股价跌0.21%,报收4.82元,成交金额1865万元,换手率0.11%,振幅3.73%,量比0.70。远大医药今日主力资金净流出230万元,连续3日净流出,上一交易日主力净流出288万元,今日环比减少20.14%。近一年数据显示,该股主力连续3日净流出后,次日下跌概率为66.67%,平均跌幅为1.50%。该股近5个交易日下跌0.41%,主力资金累计净流出141万元,其中1个交易日为股价上涨时净流出;近20日主力资金累计净流入127万元,其中净流入天数为11日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024061416161595afbac5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024061416161595afbac5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["00512","BK1191"],"gpt_icon":0},{"id":"2443579816","title":"远大医药06月13日遭主力抛售288万元 环比增加294.52%","url":"https://stock-news.laohu8.com/highlight/detail?id=2443579816","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2443579816?lang=zh_cn&edition=full","pubTime":"2024-06-13 16:16","pubTimestamp":1718266617,"startTime":"0","endTime":"0","summary":"06月13日, 远大医药股价涨0.21%,报收4.83元,成交金额2531万元,换手率0.15%,振幅3.94%,量比1.06。远大医药今日主力资金净流出288万元,上一交易日主力净流出73万元,今日环比增加294.52%。该股近5个交易日上涨1.47%,主力资金累计净流入95万元,其中2个交易日为股价下跌时净流入;近20日主力资金累计净流出226万元,其中净流出天数为8日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024061316175095abe51c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024061316175095abe51c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","00512"],"gpt_icon":0},{"id":"2442119853","title":"远大医药(00512.HK)创新眼科药物完成首例患者入组给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2442119853","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2442119853?lang=zh_cn&edition=full","pubTime":"2024-06-12 00:41","pubTimestamp":1718124060,"startTime":"0","endTime":"0","summary":"远大医药(00512.HK) 公布,集团用于延缓儿童近视进展的全球创新眼科药物GPN00884在内地开展的I期临床研究,近日完成了首例患者入组给药。该研究是一项随机、双盲、安慰剂对照、剂量递增的I期临床试验,拟入组40例健康受试者,旨在评估GPN00884滴眼液在健康受试者中单次及多次给药后的安全性、耐受性和药代动力学特征。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2024-06-11 16:25。)AASTOCKS新闻","market":"hk","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20240508115941767_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20240508115941767_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1355656/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1191","00512"],"gpt_icon":0},{"id":"2442986318","title":"远大医药GPN00884国内I期临床完成首例患者入组给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2442986318","media":"证券时报网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2442986318?lang=zh_cn&edition=full","pubTime":"2024-06-11 22:50","pubTimestamp":1718117417,"startTime":"0","endTime":"0","summary":"证券时报e公司讯,6月11日,远大医药公告称,用于延缓儿童近视进展的全球创新眼科药物GPN00884在中国开展的I期临床研究,已于近日顺利完成首例患者入组给药。根据公告,本次完成首例患者入组给药的是一项随机、双盲、安慰剂对照、剂量递增的I期临床试验,拟入组40例健康受试者,旨在评估GPN00884滴眼液在健康受试者中单次及多次给药后的安全性、耐受性和药代动力学特征。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202406113101061043.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202406113101061043.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["00512","BK1191"],"gpt_icon":0},{"id":"2442369920","title":"远大医药(00512):全球创新眼科药物GPN00884在中国开展的I期临床研究完成了首例患者入组给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2442369920","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2442369920?lang=zh_cn&edition=full","pubTime":"2024-06-11 18:51","pubTimestamp":1718103086,"startTime":"0","endTime":"0","summary":"智通财经APP讯,远大医药 发布公告,集团用于延缓儿童近视进展的全球创新眼科药物GPN00884在中国开展的I期临床研究,近日完成了首例患者入组给药。GPN00884滴眼液有望为医生和患者提供一种全新的延缓儿童近视进展的临床治疗方案。中国是全球近视人数最多的国家,根据国家卫生健康委员会调查结果,中国青少年近视患病率高居世界第一。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1133654.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["00884","BK1191","BK1555","BK1240","00512"],"gpt_icon":0},{"id":"2442695513","title":"远大医药(00512)GPN00884国内I期临床完成首例患者入组给药,或破局过亿近视防治市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2442695513","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2442695513?lang=zh_cn&edition=full","pubTime":"2024-06-11 18:47","pubTimestamp":1718102848,"startTime":"0","endTime":"0","summary":"6月11日,港股科技创新型国际化医药企业远大医药五官科板块传来利好,公司用于延缓儿童近视进展的全球创新眼科药物GPN00884在中国开展的I期临床研究,已于近日顺利完成首例患者入组给药。图片来源:远大医药微信公众号以用于眼科术后抗炎镇痛的激素纳米混悬滴眼液GPN00833 为例,该产品于2023年10月完成中国III期临床试验的首例患者入组给药,并在今年3月获得美国FDA批准上市。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1133657.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","00512"],"gpt_icon":0},{"id":"2441103942","title":"远大医药06月07日获主力加仓259万元 环比增加4216.67%","url":"https://stock-news.laohu8.com/highlight/detail?id=2441103942","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2441103942?lang=zh_cn&edition=full","pubTime":"2024-06-07 16:15","pubTimestamp":1717748121,"startTime":"0","endTime":"0","summary":"06月07日, 远大医药股价涨1.04%,报收4.87元,成交金额3062万元,换手率0.17%,振幅4.77%,量比1.44。远大医药今日主力资金净流入259万元,连续4日净流入,上一交易日主力净流入6万元,今日环比增加4216.67%。近一年数据显示,该股主力连续4日净流入后,次日上涨概率为75.00%,平均涨幅为0.89%。该股近5个交易日上涨5.14%,主力资金累计净流入314万元,其中2个交易日为股价下跌时净流入;近20日主力资金累计净流出327万元,其中净流出天数为8日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406071615359597b395&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406071615359597b395&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","00512"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.chinagrandpharm.com","stockEarnings":[{"period":"1week","weight":-0.0235},{"period":"1month","weight":-0.0498},{"period":"3month","weight":0.1566},{"period":"6month","weight":0.2446},{"period":"1year","weight":0.0505},{"period":"ytd","weight":0.1198}],"compareEarnings":[{"period":"1week","weight":0.0117},{"period":"1month","weight":-0.0119},{"period":"3month","weight":0.0908},{"period":"6month","weight":0.1518},{"period":"1year","weight":-0.0868},{"period":"ytd","weight":0.0399}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"远大医药健康控股有限公司是一家主要从事制造及销售医药制剂及医疗器械的香港投资控股公司。该公司主要从事制造及销售医药制剂及医疗器械、生物技术产品及营养产品、精品原料药和其他产品。该公司的主要产品涵盖抗肿瘤、心血管急救制剂及高端心脑血管介入医疗器械、抗病毒抗感染、呼吸及五官科以及生物健康产品和精品原料药。","yearOnYearQuotes":[{"month":1,"riseRate":0.482759,"avgChangeRate":0.094346},{"month":2,"riseRate":0.689655,"avgChangeRate":0.105408},{"month":3,"riseRate":0.37931,"avgChangeRate":0.012932},{"month":4,"riseRate":0.62069,"avgChangeRate":0.018409},{"month":5,"riseRate":0.448276,"avgChangeRate":0.071029},{"month":6,"riseRate":0.344828,"avgChangeRate":-0.050119},{"month":7,"riseRate":0.37931,"avgChangeRate":-0.014316},{"month":8,"riseRate":0.392857,"avgChangeRate":0.004418},{"month":9,"riseRate":0.464286,"avgChangeRate":-0.045547},{"month":10,"riseRate":0.535714,"avgChangeRate":-0.01036},{"month":11,"riseRate":0.535714,"avgChangeRate":0.091557},{"month":12,"riseRate":0.5,"avgChangeRate":-0.008312}],"exchange":"SEHK","name":"远大医药","nameEN":"GRAND PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"远大医药(00512)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供远大医药(00512)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"远大医药,00512,远大医药股票,远大医药股票老虎,远大医药股票老虎国际,远大医药行情,远大医药股票行情,远大医药股价,远大医药股市,远大医药股票价格,远大医药股票交易,远大医药股票购买,远大医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"远大医药(00512)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供远大医药(00512)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}